Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22375469 | 0.86 | FOLH1 (0.33) | FOLH1CHRM2CHRM4CHRM1 | |
| SCHEMBL21465910 | 0.85 | ALB (0.39) | FOLH1 | |
| SCHEMBL22375760 | 0.84 | ADRB2 (0.31) | CNR2FOLH1 | |
| SCHEMBL13539964 | 0.84 | CHRM2 (0.47) | FOLH1CHRM2CHRM4CHRM1 | |
| SCHEMBL14950991 | 0.83 | FOLH1 (0.32) | CNR2FOLH1CHRM2CHRM4CHRM1 | |
| SCHEMBL13448062 | 0.83 | FOLH1 (0.39) | CNR2FOLH1 | |
| SCHEMBL16446180 | 0.83 | FOLH1 (0.39) | CNR2FOLH1 | |
| SCHEMBL15706851 | 0.83 | FOLH1 (0.32) | CNR2FOLH1CHRM2CHRM4CHRM1 | |
| SCHEMBL24012449 | 0.83 | FOLH1 (0.30) | FOLH1 | |
| SCHEMBL24012407 | 0.81 | CNR2 (0.32) | CNR2FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210346509-A1 | GLP-1 Receptor Ligand Moiety Conjugated Oligonucleotides and Uses Thereof | ASTRAZENECA AB (SE) | 2021-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210346509-A1 | GLP-1 Receptor Ligand Moiety Conjugated Oligonucleotides and Uses Thereof | GLP1R, GIPR, GRPR | CNR2 1908/4885FOLH1 149/4885CHRM2 4049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.